期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 86, 期 5, 页码 566-569出版社
WILEY
DOI: 10.1038/clpt.2009.137
关键词
-
资金
- NIDDK NIH HHS [K23 DK071636, K23 DK071636-04] Funding Source: Medline
With its rising incidence and prevalence, chronic kidney disease (CKD) is a major public health concern, both in the United States and worldwide. Recent worldwide initiatives have attempted to garner attention for CKD by emphasizing that the condition is common, harmful, and treatable.(1) In the United States, as many as 26 million adults may have CKD, an increase from similar to 10% of the US adult population between 1988 and 1994 to >13% just one decade later. 2,3 Similar rates have been seen worldwide, with a CKD prevalence of 13% in Beijing, China(4) and 16% in Australia. 5 In the United States, the dramatic rise in the prevalence of CKD likely reflects similar increases in obesity and its sequelae-namely, diabetes, hypertension, and cardiovascular disease.(3) The prevalence of CKD, as well as its associated costs, is expected to continue to increase.(6)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据